CORCEPT THERAPEUTICS INC Sales Revenue, Goods, Net (Deprecated 2018-01-31)
CORCEPT THERAPEUTICS INC (CORT) reported Sales Revenue, Goods, Net (Deprecated 2018-01-31) of $57.66 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SalesRevenueGoodsNet · last filed 2018-05-09
- CORCEPT THERAPEUTICS INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $57.66M, a 108.92% increase year-over-year.
- CORCEPT THERAPEUTICS INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $53.28M, a 123.76% increase year-over-year.
- CORCEPT THERAPEUTICS INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $42.76M, a 96.84% increase year-over-year.
- CORCEPT THERAPEUTICS INC sales revenue, goods, net (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $35.56M, a 80.28% increase year-over-year.
- CORCEPT THERAPEUTICS INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2017 was $159.20M, a 95.77% increase from fiscal 2016.
- CORCEPT THERAPEUTICS INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2016 was $81.32M, a 61.72% increase from fiscal 2015.
- CORCEPT THERAPEUTICS INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2015 was $50.29M, a 89.39% increase from fiscal 2014.
- CORCEPT THERAPEUTICS INC sales revenue, goods, net (deprecated 2018-01-31) for fiscal 2014 was $26.55M, a 156.36% increase from fiscal 2013.
| Period end | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 3 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 6 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 9 month | Sales Revenue, Goods, Net (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $57.66M 10-Q · filed 2018-05-09 | $110.94M derived: sum of 2 quarters · filed 2018-05-09 | $153.70M derived: sum of 3 quarters · filed 2018-05-09 | $189.26M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-12-31 | $53.28M 10-K · filed 2018-02-28 | $96.04M derived: sum of 2 quarters · filed 2018-02-28 | $131.60M derived: sum of 3 quarters · filed 2018-02-28 | $159.20M 10-K · filed 2018-02-28 |
| 2017-09-30 | $42.76M 10-K · filed 2018-02-28 | $78.32M derived: sum of 2 quarters · filed 2018-02-28 | $105.92M 10-Q · filed 2017-11-03 | $129.73M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-06-30 | $35.56M 10-K · filed 2018-02-28 | $63.16M 10-Q · filed 2017-08-02 | $86.97M derived: sum of 3 quarters · filed 2018-05-09 | $108.69M derived: sum of 4 quarters · filed 2018-05-09 |
| 2017-03-31 | $27.60M 10-Q · filed 2018-05-09 | $51.41M derived: sum of 2 quarters · filed 2018-05-09 | $73.14M derived: sum of 3 quarters · filed 2018-05-09 | $92.86M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $23.81M 10-K · filed 2018-02-28 | $45.54M derived: sum of 2 quarters · filed 2018-02-28 | $65.26M derived: sum of 3 quarters · filed 2018-02-28 | $81.32M 10-K · filed 2018-02-28 |
| 2016-09-30 | $21.73M 10-K · filed 2018-02-28 | $41.45M derived: sum of 2 quarters · filed 2018-02-28 | $57.51M 10-Q · filed 2017-11-03 | $72.48M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-06-30 | $19.72M 10-K · filed 2018-02-28 | $35.78M 10-Q · filed 2017-08-02 | $50.75M derived: sum of 3 quarters · filed 2018-02-28 | $64.01M derived: sum of 4 quarters · filed 2018-02-28 |
| 2016-03-31 | $16.06M 10-K · filed 2018-02-28 | $31.03M derived: sum of 2 quarters · filed 2018-02-28 | $44.29M derived: sum of 3 quarters · filed 2018-02-28 | $56.24M derived: sum of 4 quarters · filed 2018-02-28 |
| 2015-12-31 | $14.97M 10-K · filed 2017-03-06 | $28.23M derived: sum of 2 quarters · filed 2017-03-06 | $40.18M derived: sum of 3 quarters · filed 2017-03-06 | $50.29M 10-K · filed 2018-02-28 |
| 2015-09-30 | $13.26M 10-K · filed 2017-03-06 | $25.22M derived: sum of 2 quarters · filed 2017-03-06 | $35.32M 10-Q · filed 2016-11-02 | $44.33M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-06-30 | $11.96M 10-K · filed 2017-03-06 | $22.06M 10-Q · filed 2016-08-03 | $31.07M derived: sum of 3 quarters · filed 2017-03-06 | $38.35M derived: sum of 4 quarters · filed 2017-03-06 |
| 2015-03-31 | $10.10M 10-K · filed 2017-03-06 | $19.11M derived: sum of 2 quarters · filed 2017-03-06 | $26.40M derived: sum of 3 quarters · filed 2017-03-06 | $32.25M derived: sum of 4 quarters · filed 2017-03-06 |
| 2014-12-31 | $9.01M 10-K · filed 2016-03-10 | $16.30M derived: sum of 2 quarters · filed 2016-03-10 | $22.15M derived: sum of 3 quarters · filed 2016-03-10 | $26.55M 10-K · filed 2017-03-06 |
| 2014-09-30 | $7.28M 10-K · filed 2016-03-10 | $13.13M derived: sum of 2 quarters · filed 2016-03-10 | $17.54M 10-Q · filed 2015-11-06 | $21.65M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-06-30 | $5.85M 10-K · filed 2016-03-10 | $10.26M 10-Q · filed 2015-08-07 | $14.37M derived: sum of 3 quarters · filed 2016-03-10 | $17.00M derived: sum of 4 quarters · filed 2016-03-10 |
| 2014-03-31 | $4.41M 10-K · filed 2016-03-10 | $8.52M derived: sum of 2 quarters · filed 2016-03-10 | $11.15M derived: sum of 3 quarters · filed 2016-03-10 | $13.04M derived: sum of 4 quarters · filed 2016-03-10 |
| 2013-12-31 | $4.12M 10-K · filed 2015-03-13 | $6.75M derived: sum of 2 quarters · filed 2015-03-13 | $8.64M derived: sum of 3 quarters · filed 2015-03-13 | $10.36M 10-K · filed 2016-03-10 |
| 2013-09-30 | $2.63M 10-K · filed 2015-03-13 | $4.53M derived: sum of 2 quarters · filed 2015-03-13 | $6.24M 10-Q · filed 2014-11-07 | $7.62M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-06-30 | $1.89M 10-K · filed 2015-03-13 | $3.61M 10-Q · filed 2014-08-08 | $4.99M derived: sum of 3 quarters · filed 2015-03-13 | $6.04M derived: sum of 4 quarters · filed 2015-03-13 |
| 2013-03-31 | $1.72M 10-K · filed 2015-03-13 | $3.09M derived: sum of 2 quarters · filed 2015-03-13 | $4.15M derived: sum of 3 quarters · filed 2015-03-13 | $5.02M derived: sum of 4 quarters · filed 2015-03-13 |
| 2012-12-31 | $1.38M 10-K · filed 2014-03-14 | $2.43M derived: sum of 2 quarters · filed 2014-03-14 | $3.31M derived: sum of 3 quarters · filed 2014-03-14 | $3.31M 10-K · filed 2015-03-13 |
| 2012-09-30 | $1.05M 10-K · filed 2014-03-14 | $1.93M derived: sum of 2 quarters · filed 2014-03-14 | $1.93M 10-Q · filed 2013-11-12 | |
| 2012-06-30 | $875.00K 10-K · filed 2014-03-14 | $875.00K 10-Q · filed 2013-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |